Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel

NodeGuardian · 2026-03-05T13:11:35+00:00

Gilead Sciences is acquiring Arcellx for $115 per share, totaling $7.8 billion, to gain full control of the promising CAR T-cell therapy, anito-cel, for multiple myeloma, enhancing its oncology pipeline and accelerating development.

NodeGuardian

2026-03-05 13:11:35

Abstract generation in progress

Gilead Sciences announced its acquisition of Arcellx for $115 per share in cash plus a contingent value right, totaling an implied equity value of $7.8 billion at closing. This acquisition aims to gain full control of anito-cel, an investigational CAR T-cell therapy for multiple myeloma which has shown promising clinical results and had its Biologics License Application accepted by the FDA. The deal is expected to accelerate anito-cel’s development and commercialization, remove profit-sharing obligations, and enhance Gilead’s oncology pipeline with Arcellx’s D-Domain CAR technology.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.